371 related articles for article (PubMed ID: 25256603)
1. PEGylated hyaluronic acid-modified liposomal delivery system with anti-γ-glutamylcyclotransferase siRNA for drug-resistant MCF-7 breast cancer therapy.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Fu H; Zhang Z; He Q
J Pharm Sci; 2015 Feb; 104(2):476-84. PubMed ID: 25256603
[TBL] [Abstract][Full Text] [Related]
2. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
[TBL] [Abstract][Full Text] [Related]
3. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
[TBL] [Abstract][Full Text] [Related]
5. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
6. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
[TBL] [Abstract][Full Text] [Related]
7. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
10. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
11. Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells.
Li N; Fu T; Fei W; Han T; Gu X; Hou Y; Liu Y; Yang J
J Pharm Pharmacol; 2019 Aug; 71(8):1243-1254. PubMed ID: 31215039
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
13. Blockade of γ-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells.
Takagi H; Ii H; Kageyama S; Hanada E; Taniguchi K; Yoshiya T; Chano T; Kawauchi A; Nakata S
Anticancer Res; 2019 Sep; 39(9):4811-4816. PubMed ID: 31519583
[TBL] [Abstract][Full Text] [Related]
14. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel.
Li J; Yin T; Wang L; Yin L; Zhou J; Huo M
Int J Pharm; 2015 Apr; 483(1-2):38-48. PubMed ID: 25655715
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
17. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
18. Identification of U83836E as a γ-glutamylcyclotransferase inhibitor that suppresses MCF7 breast cancer xenograft growth.
Ii H; Nohara Y; Yoshiya T; Masuda S; Tsuda S; Oishi S; Friedman J; Kawabe T; Nakata S
Biochem Biophys Res Commun; 2021 Apr; 549():128-134. PubMed ID: 33676180
[TBL] [Abstract][Full Text] [Related]
19. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
